Response Biomedical | GenomeWeb

Response Biomedical

NEW YORK (GenomeWeb News) – Response Biomedical today said that it has signed a new, nonexclusive deal for Fisher HealthCare to distribute its portfolio of infectious disease tests in the US.

NEW YORK (GenomeWeb News) – Response Biomedical announced on Thursday a US distribution deal covering its cardiovascular portfolio of Ramp products.

NEW YORK (GenomeWeb News) – Response Biomedical said today that revenues in the third quarter increased 69 percent year over year.

NEW YORK (GenomeWeb News) – Response Biomedical said today that as a result of the termination of a collaboration with 3M and 3M Innovative Properties, it has regained the worldwide rights to Flu A+B and respiratory syncytial virus products.

NEW YORK (GenomeWeb News) – Response Biomedical has completed a 20-for-one share consolidation, the Vancouver, British Columbia-based firm said yesterday after the close of the market.

NEW YORK (GenomeWeb News) – Response Biomedical today said that revenues in the second quarter increased 10 percent year over year with particular strength in cardiovascular product sales.

Response Biomedical said this week that Jonathan Wang has been appointed to the company's board of directors.

Response Biomedical said this week that its board of directors has appointed Jeffrey Purvin to be CEO and a director, and that Peter Thompson has stepped down from the interim CEO position that he has held for nearly one year.

NEW YORK (GenomeWeb News) – Response Biomedical said today that it has received C$283,756 (US$279,640) from the Canadian government to support its Ramp point-of-care platform.

NEW YORK (GenomeWeb News) – Response Biomedical today reported that product sales for the first quarter rose 50 percent year over year on the strength of its cardiovascular tests.

Pages

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.